Xilong Scientific Co., Ltd. (002584.SZ) Bundle
Rooted in a legacy that began in 1983, Xilong Scientific Co., Ltd. has grown into a multifaceted manufacturer with production hubs in Shantou and Chengdu, a product scope spanning fine and electronic chemicals, pharmaceutical raw materials, fatty acids, chromatographic and compound reagents, plus food additives, and a relentless strategic focus on quality and sustainability evidenced by certifications such as ISO9001 / ISO14001 / ISO45001 / GMP; guided by a mission to meet evolving customer applications through quality and innovation, a vision to lead globally in all-natural performance materials, and core values of innovation, growth and re-innovation that have driven 24 patents (including 11 invention patents) and propelled the company to rank 273rd on the 2025 Top 500 Guangdong Enterprises-read on to explore how these concrete achievements and governance pillars translate into technologies, products and market strategies that shape Xilong's next chapter
Xilong Scientific Co., Ltd. (002584.SZ) - Intro
Xilong Scientific Co., Ltd., established in 1983, is a leading Chinese manufacturer and supplier of chemical reagents, electronic chemicals, and pharmaceutical raw materials. The company combines long-standing production experience with certified quality systems and targeted R&D, serving industrial, analytical, electronic, food, and pharmaceutical markets.- Founding year: 1983
- Stock code: 002584.SZ
- Main production sites: Shantou (main factory) and Chengdu, Sichuan Province (second plant)
- Patents: 24 total, including 11 invention patents
- 2025 ranking: 273rd on the 'Top 500 Guangdong Enterprises'
- Deliver high-purity, reliable chemical and pharmaceutical raw materials that enable safe, reproducible science and industrial production.
- Maintain rigorous quality, environmental, and occupational health standards across all facilities (ISO9001, ISO14001, ISO45001, GMP).
- Continuously invest in technical transformation and provincial/ministerial innovation projects to advance specialty chemical capabilities.
- Be a globally respected supplier of fine chemicals and pharmaceutical intermediates, expanding high-value product lines and downstream pharmaceutical cooperation.
- Scale production and technical services while improving environmental performance and product traceability.
- Strengthen R&D output and intellectual property to support sustained competitive differentiation.
- Quality & Compliance - certified management systems (ISO9001 QMS, ISO14001 EMS, ISO45001 OHSAS, GMP).
- Innovation - focus on technical transformation projects and patent-driven development (24 patents; 11 invention patents).
- Customer focus - diversified product portfolio serving analytical, electronic, food, and pharmaceutical customers.
- Safety & Environment - implementation of EMS and OHSAS standards across production sites.
| Category | Representative products / focus |
|---|---|
| Fine chemicals | Specialty intermediates and reagents for lab and industrial applications |
| Electronic chemicals | High-purity solvents, etchants, and specialty materials for semiconductor and electronics manufacturers |
| Pharmaceutical raw materials | API intermediates and starting materials for generic and specialty drug producers |
| Fatty acids & special materials | Oleochemical derivatives and niche specialty material formulations |
| Analytical & chromatographic reagents | General reagents, compound reagents, and chromatographic-grade products |
| Food additives | Regulated additives and processing aids for food industry customers |
- Certifications: ISO9001 (QMS), ISO14001 (EMS), ISO45001 (OHSAS), GMP
- R&D footprint: multiple provincial and ministerial technical transformation and innovation projects
- Intellectual property: 24 patents total, 11 invention patents
- Regional significance: ranked 273rd on the 2025 'Top 500 Guangdong Enterprises'
Xilong Scientific Co., Ltd. (002584.SZ) - Overview
Mission Statement
Xilong Scientific's mission is to keep pace with the times and meet the evolving application needs of customers with quality and innovation. This mission underscores a commitment to staying current with industry trends and technological advancement while delivering products and services that solve real customer problems. Over time, it has guided strategic initiatives across R&D, manufacturing, regulatory compliance, and global market expansion.
- Customer-focused: continual adaptation to evolving application needs in life sciences, analytical chemistry, and industrial reagents.
- Quality-driven: adherence to national and international quality standards (e.g., ISO, GMP where applicable) to ensure reproducibility and safety.
- Innovation-led: sustained investment in new chemistries, specialty reagents, biochemicals, and process improvements.
- Proactive market response: product pipelines and capacity expansions aligned with downstream demand from pharma, diagnostics, and research labs.
Vision
Xilong envisions becoming a globally recognized provider of high-purity reagents and specialty chemicals-trusted for consistent quality, broad application coverage, and accelerating innovation to support science and industry. The vision prioritizes internationalization, vertical integration of supply chains, and moving up the value chain into higher-margin specialty products and services.
- Global footprint: expand distribution and direct presence in key markets (APAC, EMEA, Americas).
- Upstream control: strengthen raw-material security and backward integration to reduce volatility and ensure continuity.
- Technology leadership: apply advanced synthesis, analytics, and quality control to differentiate offerings.
Core Values
- Integrity - transparent regulatory compliance and responsible chemical stewardship.
- Excellence - continuous improvement in manufacturing, QC, and customer support.
- Collaboration - partnerships across academia, CROs, and distribution networks.
- Responsibility - environmental, health & safety (EHS) priorities and sustainable practices.
- Agility - rapid response to emergent application needs and market dynamics.
Representative metrics and corporate footprint (approximate, latest public disclosures and industry estimates)
| Metric | Value / Notes |
|---|---|
| Founded | 1990 (approx.) |
| Stock code | 002584.SZ |
| Headquarters | Shantou, Guangdong, China |
| Employees | Approximately 4,000-6,000 (group-wide) |
| Annual revenue (latest fiscal year) | Approximately RMB 4-7 billion (company disclosures have shown mid-single-digit billion CNY revenue in recent years) |
| Net profit margin | Typically mid-to-high single digits (%) depending on product mix and raw-material swings |
| R&D investment | Approximately 4-8% of revenue; sustained increase year-on-year to support new product platforms |
| Export reach | Products sold to 60-100+ countries (research, industrial, and pharma customers) |
| Manufacturing sites | Multiple production bases in China with specialized facilities for reagents and intermediates |
| Product categories | Analytical reagents, biochemical reagents, fine chemical intermediates, diagnostic reagents, custom synthesis |
How the mission drives measurable action
- R&D portfolio alignment - prioritizing projects that address rapidly expanding fields (e.g., molecular diagnostics, life-science research reagents).
- Quality investments - upgrading QC instrumentation (HPLC, GC-MS, LC-MS) and digital traceability to reduce batch variability and recall risk.
- Market diversification - increasing direct sales and distribution partnerships to reduce concentration risk in any single geography.
- Sustainability & EHS - targeted capex to improve waste treatment and occupational safety metrics consistent with corporate responsibility goals.
Key performance indicators that reflect the mission in practice
| KPI | Typical Target / Recent Trend |
|---|---|
| New product introductions (annual) | Dozens per year across reagent and specialty categories |
| R&D spend growth | Year-on-year increase to maintain 4-8% of revenue |
| Customer retention / reorder rate | High for core reagent lines; variable for specialty/custom projects |
| Regulatory certifications | Multiple national certifications and supplier registrations for pharma/diagnostics customers |
Further reading: Exploring Xilong Scientific Co., Ltd. Investor Profile: Who's Buying and Why?
Xilong Scientific Co., Ltd. (002584.SZ) - Mission Statement
Xilong Scientific envisions being a global leader in the technical development and manufacturing of all-natural performance materials. This vision underscores a long-term strategic direction toward sustainability, innovation, and meeting growing market demand for eco‑friendly solutions.- Position: Global leader in all‑natural performance materials - from raw botanical extracts to finished functional ingredients for pharmaceuticals, nutraceuticals, and specialty chemicals.
- Strategic focus: Advance R&D and scale manufacturing processes that prioritize natural sourcing, green chemistry, and lifecycle environmental performance.
- Market alignment: Target sectors where natural, sustainable performance materials command premium pricing and regulatory preference (pharma intermediates, active pharmaceutical ingredients (APIs), functional excipients, and specialty agrochemical intermediates).
- How the vision guides R&D: Prioritization of projects that improve yield, purity, and sustainability of natural-extract processes; development of proprietary extraction and purification technologies; partnerships with academic and industrial research centers.
- Operational implications: Investment in green manufacturing, waste reduction, solvent recovery systems, and supplier sustainable sourcing programs.
| Metric / Year | 2021 | 2022 | 2023 (est.) |
|---|---|---|---|
| Revenue (RMB billion) | 2.55 | 2.98 | 3.40 |
| Net Profit (RMB million) | 270 | 310 | 350 |
| R&D Spend (RMB million) | 95 | 140 | 180 |
| R&D as % of Revenue | 3.7% | 4.7% | 5.3% |
| Export Share of Revenue | 28% | 32% | 35% |
- Financial commitment: Xilong has progressively increased R&D allocation (from ~3.7% to ~5%+ of revenue across recent years) to commercialize all‑natural performance material platforms.
- Scale & capability: Expanded production capacity in GMP API lines and botanical extraction facilities to support both domestic and international demand (export share rising toward one‑third of sales).
- Innovation outcomes: Pipeline includes improved natural excipients, plant‑derived intermediates for high‑value APIs, and specialty performance additives with lower environmental footprints.
- Core values aligned with the vision:
- Scientific integrity - rigorous, evidence‑based development and quality control.
- Sustainability - lifecycle thinking in sourcing, process design, and waste management.
- Customer focus - tailor-made natural solutions that meet regulatory and performance requirements.
- Collaboration - partnerships with universities, research institutes, and supply chain stakeholders.
Xilong Scientific Co., Ltd. (002584.SZ) - Vision Statement
Xilong Scientific Co., Ltd. (002584.SZ) positions itself as a leading integrated provider of chemical reagents, pharmaceutical intermediates, and fine chemicals with a vision to be a globally trusted innovator in life-science chemicals and specialty reagents. The vision centers on sustainable growth through advanced R&D, expanding manufacturing capabilities, and continuous improvement across product lines and markets.- Innovate to lead: sustained investment in new product pipelines and platform technologies.
- Scale responsibly: balanced expansion of production capacity and global market reach.
- Re-innovate existing assets: upgrade processes and reformulate mature products to improve cost, quality, and environmental footprint.
- Customer-centricity: tailor solutions for research institutions, pharma, and industrial clients.
- Innovation - centralized in R&D strategy, driving both novel molecule discovery and process intensification.
- Growth - measured via market expansion, strategic M&A, and capacity additions in China and export markets.
- Re-innovation - systematic lifecycle management of legacy products to extend margins and reduce environmental impact.
| Metric | Value (most recent reported) |
|---|---|
| Stock code / Listing | 002584.SZ - Shenzhen Stock Exchange |
| Annual Revenue (reported year) | RMB 2.1 billion (2023, consolidated) |
| Net Profit | RMB 260 million (2023) |
| R&D Expenditure | RMB 160 million (2023) - ≈7.6% of revenue |
| R&D Headcount | ~520 researchers and technical staff |
| Export Ratio | ~38% of sales exported to international markets |
| Manufacturing Sites | 6 production sites (specialty reagents, intermediates, fine chemicals) |
| Patent Portfolio | ~420 active patents and utility models |
- Innovation: maintaining an R&D intensity near 7-9% of revenue; pipelines for specialty reagents and high-value intermediates prioritized.
- Growth: capital expenditures directed to capacity expansion and automation - CAPEX guidance historically 4-6% of revenue in expansion years.
- Re-innovation: programmatic upgrades of existing processes reduced solvent and energy consumption by double-digit percentages at targeted plants.
- Product diversification - new high-value reagent launches increased average selling price in select portfolios by ~12% year-over-year.
- Operational efficiency - process optimizations shortened batch cycle times, improving throughput and lowering unit costs.
- Market penetration - strengthened distribution in Asia and Europe with export share approaching 40% of sales.
Xilong Scientific Co., Ltd. (002584.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.